ArticleFrontiers in medicine2025
Correlation and risk factor analysis of multifidus muscle atrophy in degenerative lumbar spondylolisthesis.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Sarcopenia is associated with degenerative lumbar spondylolisthesis but does not compromise surgical outcomes: a retrospective study in Japan.Asian spine journal · 2026Article
- Paravertebral muscle degeneration-guided selective fusion strategy for degenerative lumbar scoliosis: a novel approach to minimize surgical invasiveness while optimizing clinical outcomes.Frontiers in medicine · 2026Article
- Correlation analysis between multifidus muscle atrophy and the severity of degenerative scoliosis retrospective, cross-sectional study.Scientific reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: We evaluated differences in multifidus muscle atrophy (MMA) among patients with degenerative lumbar spondylolisthesis (DLS) across various segments and grades of spondylolisthesis, analysed the correlation between DLS and MMA, identified risk factors contributing to MMA, and provided a clinical reference for the prevention and treatment of MMA. Methods: This retrospective study analysed data from 213 patients diagnosed with single-segment DLS between September 2020 and January 2022. Participants were categorised into three groups based on the affected spinal segment: L3 ( Results: The LCSA/GCSA ratio at the spondylolisthesis segment was significantly lower than that at the non-spondylolisthesis segment ( Conclusion: DLS patients exhibit MMA, with more pronounced atrophy at the spondylolisthesis-affected segment. Age, BMI, and osteoporosis are independent risk factors for MMA progression in DLS patients. Clinically, it is crucial to identify and monitor high-risk patients with these factors and implement early preventive and therapeutic interventions to mitigate disease progression.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.